Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Jun 21

PMID 29922595

Authors

Kentaro Serizawa

Hirokazu Tanaka

Yasuyoshi Morita

Takahide Taniguchi

Takashi Ashida

Itaru Matsumura

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal disorders of hematopoietic stem cells, characterized by dysplastic hematopoiesis and dysregulated immune system resulting in various clinical conditions. Paraneoplastic inflammatory syndromes, which are well known to be associated with MDS, show response to immune-modulated therapy and often disappear during the course of hematologic management. Azacitidine (5-Aza) was shown to prolong survival of high-risk MDS patients, however, the effects of 5-Aza on paraneoplastic inflammation in MDS have yet to be elucidated. 5-Aza was administered to a 60-year-old man with MDS accompanying Sweet's syndrome at a dose of 75 mg/m/daily subcutaneously for 7 days every 28 days. 5-Aza was not only effective in controlling systemic symptoms caused by paraneoplastic inflammation, but hematologic improvements were also observed after four cycles of the 5-Aza treatment. Immune profiling in peripheral blood before and after 5-Aza treatment revealed that the effector and naive regulatory T cells in lymphocytes drastically increased after the 5-Aza treatment, i.e., 5-Aza might induce a shift in lymphocytic populations toward immunosuppression in this patient. Our results raised the immune-mediated effect of 5-Aza on both dysplastic hematopoiesis and paraneoplastic inflammation in myelodyplastic syndromes.

References

Pilorge S, Doleris L, Dreyfus F, Park S . The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases. Br J Haematol. 2011; 153(5):664-5. DOI: 10.1111/j.1365-2141.2010.08557.x. View

Enright H, JACOB H, Vercellotti G, Howe R, Belzer M, Miller W . Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 1995; 91(2):403-8. DOI: 10.1111/j.1365-2141.1995.tb05310.x. View

Aggarwal S, van de Loosdrecht A, Alhan C, Ossenkoppele G, Westers T, Bontkes H . Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol. 2011; 153(5):568-81. DOI: 10.1111/j.1365-2141.2011.08683.x. View

Fraison J, Mekinian A, Grignano E, Kahn J, Arlet J, Decaux O . Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016; 43:13-7. DOI: 10.1016/j.leukres.2016.02.005. View

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

Costantini B, Kordasti S, Kulasekararaj A, Jiang J, Seidl T, Perez Abellan P . The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica. 2012; 98(8):1196-205. PMC: 3729899. DOI: 10.3324/haematol.2012.074823. View

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6):899-911. DOI: 10.1016/j.immuni.2009.03.019. View

Sanchez-Abarca L, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C . Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2009; 115(1):107-21. DOI: 10.1182/blood-2009-03-210393. View

Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas A, Moutsopoulos H . Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford). 2004; 43(5):626-32. DOI: 10.1093/rheumatology/keh136. View

10.

Fozza C, Contini S, Galleu A, Simula M, Virdis P, Bonfigli S . Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol. 2009; 37(8):947-55. DOI: 10.1016/j.exphem.2009.04.009. View

11.

Agha A, Bateman H, Sterrett A, Valeriano-Marcet J . Myelodysplasia and malignancy-associated vasculitis. Curr Rheumatol Rep. 2012; 14(6):526-31. DOI: 10.1007/s11926-012-0281-3. View

12.

de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Levesque H . Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken). 2011; 63(8):1188-94. DOI: 10.1002/acr.20504. View

13.

Cohen P . Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007; 2:34. PMC: 1963326. DOI: 10.1186/1750-1172-2-34. View

14.

Pelosof L, Gerber D . Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010; 85(9):838-54. PMC: 2931619. DOI: 10.4065/mcp.2010.0099. View